Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery

Launched by KONKUK UNIVERSITY MEDICAL CENTER · Jul 16, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating two different ways to give a medication called tranexamic acid (TXA) to patients undergoing high-risk surgeries that are not related to the heart. TXA helps reduce bleeding during and after surgery. The study will compare two methods: one is giving TXA based on a standard approach (empirical administration), while the other is based on specific tests that measure the blood's ability to clot (goal-directed administration). Researchers want to find out if the test-based method is just as effective, or even better, at reducing bleeding and other complications like blood clots or seizures.

To participate in this trial, patients must be undergoing certain surgeries, such as spinal fusion, total hip or knee replacements, prostate surgery, or liver surgery. However, there are some important criteria that would exclude someone from joining, such as being pregnant, having a history of certain blood conditions, or having recently had a heart attack or stroke. Participants will be monitored closely during the study to ensure their safety and to gather information on how well each method works. This trial is currently looking for volunteers, and it aims to provide valuable insights into improving patient care during surgeries.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria patients undergoing following surgery
• • spinal fusion surgery with more than 2 levels
• • total hip arthroplasty
• • total knee arthroplasty
• • open prostatectomy
• • hepatectomy
• Exclusion Criteria:
• • pregnancy
• • refusal of allogenic blood transfusion
• • taking thrombin
• • history of thromboembolic and familial hypercoagulability disease
• • recent history of myocardial infarction or ischemic cerebral infarction (within 90 days)
• • hypersensitive to TXA
• • histroy of convulsion or epilepsy
• • taking hemodialysis
• • history of Heparin-induced thrombocytopenia